Immune Response Packaging Protein 
World of DTC Marketing
DECEMBER 29, 2020
These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package. While such platform technologies are a non-traditional approach, that does not mean they are untested.
pharmaphorum
JULY 18, 2022
“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. When you have mucosal immunity, the immunoglobulins called IgAs start neutralising the virus at the point of entry. The inhalant version.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 29, 2022
Bivalent vaccines work by stimulating an immune response against two different antigens, whereas monovalent vaccines only target one antigen. 5 spike protein components to their current vaccine compositions to create a two-component booster, so that the modified vaccines can potentially be used from later this year.
The Pharma Data
JUNE 25, 2021
Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.
The Pharma Data
MARCH 25, 2022
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.
Roots Analysis
OCTOBER 30, 2023
These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. Transfer RNA (tRNA): Transfer RNA is an indispensable adaptor molecule central to the translation of mRNA to proteins. In addition, they offer enhanced therapeutic and safety profiles as compared to traditional treatment approaches.
The Pharma Data
OCTOBER 14, 2020
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. About TNX-1800.
Expert insights. Personalized for you.
307 
Let's personalize your content